John J. Engelhardt

TL;DR: Data suggest that anti-CTLA-4 promotes antitumor activity by a selective reduction of intratumoral Tregs along with concomitant activation of Teffs.

TL;DR: It is determined that infiltrating tumor-specific T cells engage in long-lived interactions with bone-marrow-derived cells, proximal to the tumor, and spatiotemporal dynamics revealed here implicate nonproductive interactions between T-cells and antigen-presenting cells on the tumor margin.

TL;DR: It is revealed that distinct Fcγ receptor (FcγRs) dependency and mechanisms account for the in vivo activity of anti- PD-1 versus anti-PD-L1 Abs, which show augmented anti-tumor activity when activating F cγR binding is introduced into the molecules.

TL;DR: In vitro studies with combined ipilimumab and nivolumab showed enhanced cytokine secretion in superantigen stimulation of human peripheral blood lymphocytes and in mixed lymphocyte response assays, and dose-dependent immune-related gastrointestinal inflammation was observed with the combination therapy; this response had not been observed in previous single agent cynomolgus studies.

TL;DR: The evaluation of concurrent treatment with anti-PD-1 and anti-CTLA-4 mAbs in preclinical models results in synergistic antitumor activity whereas efficacy with sequential dosing wa...